Clinical trialPhase 2
PURIFY-TIMI 81 (YN001)
NCT07521007
Phase 2b, N≈456, randomized double-blind placebo-controlled; primary endpoint relative change coronary noncalcified plaque volume.
Also in the catalogue
- UDP-003 (Cyclarity), 7-ketocholesterol clearanceClinical trial
- YN001 + evolocumab (Australia)Clinical trial
- YN001 liposomal rosuvastatin (Beijing Inno Medicine)Clinical trial
- CTX310 Phase 1b (secondary identifier NCT07491172)Clinical trial
- VERVE-102 Heart-2Clinical trial
- Long-term follow-up of gene-editing recipients (up to 15 years)Clinical trial
Scales
Identifiers
- NCT
- NCT07521007
Original sources
Details
- Phase
- Phase 2
- Status
- Recruiting
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.